九芝堂品牌怎么样 申请店铺

我要投票 九芝堂在阿胶行业中的票数:167 更新时间:2024-12-22
九芝堂是哪个国家的品牌?「九芝堂」是 九芝堂股份有限公司 旗下著名品牌。该品牌发源于湖南省长沙市,由创始人李振国在1999-05-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
九芝堂怎么样

九芝堂股份有限公司是国家重点中药企业,国内A股上市公司,湖南省重点高新技术企业,湖南省百强企业,湖南省质量管理奖企业,长沙市工业十大标志性工程龙头企业,国家博士后科研工作站企业。

九芝堂前身“劳九芝堂药铺”创建于1650年。2004年2月,“九芝堂”商标被国家工商行政管理总局商标局认定为中国驰名商标;2006年9月,“九芝堂”被国家商务部认定为“中华老字号”;2008年6月,九芝堂传统中药文化被列入国家级非物质文化遗产保护目录。

截至2009年底,公司已发展成为拥有总资产15.48亿元,净资产12.57亿元,下辖7家直接控股子公司、3家间接控股子公司,1家分公司,年销售过12亿元,利税过3亿元的工商一体化的现代大型医药企业。

公司主要从事补血系列、补益系列、肝炎系列等中药以及调节人体免疫力的生物制剂的生产与销售,正在形成销售过亿产品、过千万产品、迅速成长产品构成的一个产品阶梯,为可持续发展奠定了产品基础。主导产品驴胶补血颗粒年销售收入超过3亿元,位于全国天然补血类产品销售前三名;以六味地黄丸为代表的浓缩丸系列销售收入突破2亿元,位于全国同种产品销售前三名;斯奇康注射液销售收入1亿元。公司的中成药片剂、浓缩丸系列产品等出口欧美、日本、东南亚等地区,其中十多种浓缩丸、片剂出口日本已将近20年。九芝堂的产品不仅是济世良药,也是一种文化载体,九芝堂人不仅是客商,也成为了文化使节。

公司综合经济实力在湖南省医药行业中排名第一,已成为湖南省“十一五”重点发展的现代中药及生物医药优势产业集群的核心企业。2006年8月,在“首届中华老字号品牌价值百强榜”上,九芝堂以13.55亿的品牌价值排在第13位。2007年4月,九芝堂被《医药经济报》评为“中国制药工业企业百强”。2008年12月,公司通过湖南省科学技术厅的再认定,蝉联“高新技术企业”称号。

“九州共济、芝兰同芳”,面对激烈的市场竞争,九芝堂谋求和谐合作,共同发展。九芝堂将秉承三百多年优良的制药传统,把自主创新作为推动公司可持续发展的主导力量,立足民生、民情,发展现代中药产业,适度介入生物制品,开发消费者最为需要的产品,改善人类健康生活,致力于成为百亿市值企业。

Jiuzhitang Co., Ltd. is a national key traditional Chinese medicine enterprise, A-share listed company in China, key high-tech enterprise in Hunan Province, top 100 enterprise in Hunan Province, quality management award enterprise in Hunan Province, ten leading industrial engineering enterprises in Changsha City, and National Postdoctoral Research Station enterprise. The predecessor of Jiuzhitang, laojiuzhitang pharmacy, was founded in 1650. In February 2004, the trademark of "Jiuzhitang" was recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and commerce; in September 2006, the trademark of "Jiuzhitang" was recognized as a "Chinese time-honored brand" by the Ministry of Commerce; in June 2008, the traditional Chinese medicine culture of Jiuzhitang was listed in the national intangible cultural heritage protection catalogue. By the end of 2009, the company has developed into a modern large-scale pharmaceutical enterprise with total assets of 1.548 billion yuan and net assets of 1.257 billion yuan. It has seven directly controlled subsidiaries, three indirectly controlled subsidiaries and one branch, with annual sales of 1.2 billion yuan and profits and taxes of 300 million yuan. The company is mainly engaged in the production and sales of traditional Chinese medicine such as blood tonic series, tonic series, hepatitis series and biological preparations regulating human immunity. It is forming a product ladder consisting of over 100 million products, over 10 million products and rapidly growing products, laying a product foundation for sustainable development. The annual sales revenue of lvjiao Buxue granules, the leading product, is more than 300 million yuan, which is located in the top three sales of natural Buxue products in China; the sales revenue of concentrated pill series represented by Liuwei Dihuang pill is more than 200 million yuan, which is located in the top three sales of the same kind of products in China; the sales revenue of Siqikang injection is 100 million yuan. The company's Chinese patent medicine tablets and concentrated pill series products are exported to Europe, America, Japan, Southeast Asia and other regions, among which more than ten kinds of concentrated pills and tablets have been exported to Japan for nearly 20 years. Jiuzhitang's products are not only good medicine for the world, but also a cultural carrier. Jiuzhitang people are not only merchants, but also cultural envoys. The company's comprehensive economic strength ranks first in the pharmaceutical industry of Hunan Province, and it has become the core enterprise of modern Chinese medicine and biomedical industry cluster which is the key development of "11th Five Year Plan" in Hunan Province. In August 2006, Jiuzhitang ranked 13th in the "top 100 list of brand value of the first time-honored Chinese brands". In April 2007, Jiuzhitang was named "top 100 pharmaceutical enterprises in China" by pharmaceutical economic news. In December 2008, the company passed the reappraisal of science and Technology Department of Hunan Province and won the title of "high and new technology enterprise". In the face of fierce market competition, Jiuzhitang seeks for harmonious cooperation and common development. Jiuzhitang will adhere to the excellent pharmaceutical tradition of more than three hundred years, take independent innovation as the leading force to promote the sustainable development of the company, based on the people's livelihood and the people's conditions, develop the modern Chinese medicine industry, moderately intervene in biological products, develop the products most needed by consumers, improve the healthy life of human beings, and strive to become a 10 billion market value enterprise.

本文链接: https://brand.waitui.com/7e3ceb284.html 联系电话:073184499762

千城特选小程序码

7×24h 快讯

新易盛:涉嫌违反限制性规定转让股票等行为 公司实际控制人高光荣被立案调查

新易盛公告,公司控股股东、实际控制人、董事长高光荣于2024年12月20日收到中国证券监督管理委员会签发的《立案通知书》,因“涉嫌违反限制性规定转让股票”等行为被立案调查。该事项现处于调查阶段,具体情况尚待有关部门的最终确认。高光荣因其个人转让股票事宜被立案调查,与公司经营无关,不会对公司产生影响,公司生产经营情况一切正常。公司将持续关注上述事项的进展情况,并严格按照有关法律、法规的规定和要求,及时履行信息披露义务。

2小时前

高德地图首发全域车道级导航

12月21日,蔚来NIO DAY上,高德地图全域车道级导航同蔚来智能电动行政旗舰ET9合作亮相,这也是高德地图车机版首发全域车道级服务,即将在蔚来更多车型得到升级搭载。

2小时前

香港财政司司长陈茂波:香港未来须推动更多跨境合作创新,进一步提升金融市场体量

香港财政司司长陈茂波12月22日在司长随笔中表示,香港未来必须推动更多制度创新、产品创新与跨境合作创新,例如开拓内地通过香港与更多新兴市场的联系,同时巩固好与传统市场的协作,进一步提升香港金融市场的体量、流动性,更好满足科技变革与地缘政局下企业与其他机构的筹融资需要,让香港国际金融中心内涵更丰富、优势更巩固、国际影响力更显著。(界面)

2小时前

湖畔实验室发布2024年创新成果

36氪获悉,12月22日,湖畔实验室(数据科学与应用浙江省实验室)发布包括AI多癌早筛、气象大模型等在内的多项年度创新成果。实验室用前沿AI技术迎战医疗、能源、农业、集成电路等产业难题,部分成果达到国际领先水平,并实现快速的落地应用,构建起“科技+产业”的正循环。作为浙江由民企牵头建设的省实验室,湖畔实验室成立于2020年7月,依托阿里巴巴达摩院建设,聚焦数据科学与应用领域。大会上,湖畔实验室进行了年度教科人一体化优秀项目颁奖和国家级博士后工作站揭牌,并与杭州电子科技大学战略合作签约。

2小时前

卡塔尔警告欧盟,欧盟新指令或致卡方停止向欧盟输送天然气

12月22日,卡塔尔能源事务国务大臣、卡塔尔能源公司总裁兼首席执行官萨阿德·卡比警告,欧盟新指令或导致卡塔尔停止向欧盟输送天然气。卡比说,如果欧盟实施《企业可持续发展尽职调查指令》,让卡塔尔能源公司损失5%的收入,那卡方宁愿不进入欧洲市场。他强调,他不是在虚张声势,因为卡塔尔能源公司的收入属于卡塔尔政府和人民,没有人会接受损失这么多资金。卡比称,欧盟应该对《企业可持续发展尽职调查指令》进行审查。欧盟理事会今年5月批准通过《企业可持续发展尽职调查指令》。该指令将在未来几年分阶段实施,对在欧盟运营的具有一定规模的企业引入强制性的环境尽职调查要求,旨在减轻或终止对环境造成的不利影响。对于违反该指令的企业,最高可被处以全球营业额5%的罚款。

2小时前

本页详细列出关于东健阿胶的品牌信息,含品牌所属公司介绍,东健阿胶所处行业的品牌地位及优势。
咨询